View Our On-Demand Webinar
Engineered NK Cells: The Next Frontier in Cancer Immunotherapy
Harnessing the immune system, particularly through CAR T cell therapies, has revolutionized cancer treatment, but challenges like cost, complexity, and risks such as graft-versus-host disease (GvHD) limit their broader use. Natural killer (NK) cells offer a promising allogeneic alternative due to their innate anti-tumor activity and HLA-independent recognition, which minimizes GvHD risk. This webinar highlights CD70 CAR NK cells as a next-generation approach, showcasing enhanced efficacy through genetic engineering and cytokine support, with promising preclinical results advancing to clinical trials for hematologic and solid tumors.
Submit the form to watch the on-demand webinar, in partnership with Prendio.
Key Learning from the Webinar:
-
NK Cells as a Scalable Allogeneic Therapy
Natural Killer (NK) cells offer a scalable, off-the-shelf alternative to autologous CAR T cells, with lower manufacturing costs, quicker availability, and minimal risk of graft-versus-host disease (GvHD).
-
CD70 as a Broad Cancer Target
CD70 is a promising target expressed across various hematologic malignancies and solid tumors but absent in most normal tissues, making it an ideal candidate for CAR-based NK therapies.
-
CAR27 NK Cells Show Enhanced Efficacy
CD70-targeting CAR NK cells, particularly those using a trCD27 construct with a CD28 co-stimulatory domain, demonstrated superior anti-tumor activity and survival benefits in preclinical models.
About the Speaker:
Sunil Acharya, PhD
Sunil Acharya, PhD, earned his doctorate in cancer biology from the MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences. He is currently a Principal Research Scientist in Dr. Katy Rezvani’s lab at MD Anderson Cancer Center, where he focuses on developing cellular immunotherapies, with a particular emphasis on Natural Killer (NK) cells. Dr. Acharya leads the preclinical research for the CD70 CAR NK project, which has advanced to Phase I/II clinical trials for treating both blood and solid tumors.
Organized by:
